Clinical Trials
65 trialsOsimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
National Institutes of Health Clinical Center (CC)
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
National Institutes of Health Clinical Center (CC)
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
GW572016 to Treat Recurrent Malignant Brain Tumors
National Institutes of Health Clinical Center (CC)
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
National Cancer Institute (NCI)
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Bevacizumab With or Without Surgery for Adult Glioblastomas
National Institutes of Health Clinical Center (CC)
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Pazopanib in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
National Cancer Institute (NCI)
Sunitinib to Treat Recurrent Brain Cancer
National Institutes of Health Clinical Center (CC)
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Bevacizumab for Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Suramin in Treating Patients With Recurrent Primary Brain Tumors
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
Carmustine Implants in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
National Cancer Institute (NCI)
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
National Cancer Institute (NCI)